Asthma and COVID-19: Аn overview of the guidelines for the management of asthma patients during the COVID-19 pandemic

The emergence of a new disease COVID-19 (coronavirus disease 2019), caused by the coronavirus named SARS-CoV-2, has significantly changed the usual interaction pattern between a doctor and a patient. Previous large studies have identified risk factors for a severe course of COVID-19, including old age, hypertension, diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease. However, asthma and respiratory allergy have not been identified as risk factors for the severe disease. These factors give clues to the pathogenesis of COVID-19, approaches to the controller medications, target therapy, allergen-specific immunotherapy (ASIT) in patients with various phenotypes and endotypes of asthma during the pandemic.

The purpose of this review is to summarize the currently available knowledge about SARS-CoV-2, T2-endotype of asthma, eosinophilic inflammation. The article provides an overview of the data from studies of COVID-19 patients with asthma, the main recommendations of the Global Initiative for Asthma (2021) and the Ministry of Health of the Russian Federation. It shows that targeting the endotypes and phenotypes of asthma can influence the management of COVID-19 patients with asthma. The influence of the imbalance of the immune system, pro-inflammatory cytokines, and effector cells in patients with asthma on the development and progression of COVID-19 is considered. Recommendations are given for the controller medications, targeted therapy, allergen-specific immunotherapy during the pandemic.

Conclusion. The current recommendations for asthma treatment, based on the latest research of COVID-19, deepen our understanding of the course of COVID-19 in patients with different phenotypes and endotypes of asthma, approaches to traditional methods of treating asthma according to clinical guidelines during the pandemic.

1. Masoli M., Fabian D., Holt S., Beasley R.; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004; 59 (5): 469–478. DOI: 10.1111/j.1398-9995.2004.00526.x.

2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017; 5 (9): 691–706. DOI: 10.1016/S2213-2600(17)30293-X.

3. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396 (10258): 1204–1222. DOI: 10.1016/S0140-6736(20)30925-9.

4. Jackson D.J., Busse W.W., Bacharier L.B. et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J. Allergy Clin. Immunol. 2020; 146 (1): 203–206.e3. DOI: 10.1016/j.jaci.2020.04.009.

5. Edwards M.R., Bartlett N.W., Hussell T. et al. The microbiology of asthma. Nat. Rev. Microbiol. 2012; 10 (7): 459–471. DOI: 10.1038/nrmicro2801.

6. Tyrrell D.A., Bynoe M.L. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966: 1 (7428): 76–77. DOI: 10.1016/s0140-6736(66)92364-6.

7. Jonsdottir H.R., Dijkman R. Coronaviruses and the human airway: a universal system for virus‐host interaction studies. Virol. J. 2016; 13: 24. DOI: 10.1186/s12985-016-0479-5.

8. Chałubiński M, Gajewski A, Kowalski ML. The relationship between human coronaviruses, asthma and allergy – an unresolved dilemma. Clin. Exp. Allergy. 2020; 50 (10): 1122–1126. DOI: 10.1111/cea.13718.

9. Shaker M.S., Oppenheimer J., Grayson M. et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J. Allergy Clin. Immunol. Pract. 2020; 8 (5): 1477–1488e5. DOI: 10.1016/j.jaip.2020.03.012.

10. Global Initiative for Asthma. GINA: Interim Guidance about COVID-19 and Asthma – Updated 26 April 2021. Available at: https://ginasthma.org

11. Ministry of Health of the Russian Federation. [Prevention, diagnosis and treatment of new coronavirus infection (COVID-19): Temporary guidelines]. Version 11 (July 05, 2021). Available at: https://bit.ly/3BdIePp . (in Russian).

12. Halpin D.M.G., Faner R., Sibila O. et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir. Med. 2020; 8 (5): 436–438. DOI: 10.1016/S2213-2600(20)30167-3.

13. Vankadari N., Wilce J.A. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg. Microbes. Infect. 2020; 9 (1): 601–604. DOI: 10.1080/22221751.2020.1739565.

14. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181 (2): 271–280e278. DOI: 10.1016/j.cell.2020.02.052.

15. Wu C., Zheng M. Single-cell RNA expression profiling shows that ACE2, the putative receptor of COVID-2019, has significant expression in nasal and mouth tissue, and is co-expressed with TMPRSS2 and not co-expressed with SLC6A19 in the tissues. Res. Square. 2020 [Preprint. Posted: March 12, 2020]. DOI: 10.21203/rs.3.rs-16992/v1.

16. Ziegler C.G.K., Allon S.J., Nyquist S.K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020; 181 (5): 1016–1035.e19. DOI: 10.1016/j.cell.2020.04.035.

17. Wölfel R., Corman V.M., Guggemos W. et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581 (7809): 465–469. DOI: 10.1038/s41586-020-2196-x.

18. Dhand R., Li J. Coughs and sneezes: their role in transmission of respiratory viral infections, including SARS-CoV-2. Am. J. Respir. Crit. Care Med. 2020; 202 (5): 651–659. DOI: 10.1164/rccm.202004-1263PP.

19. Asthma and Allergy Foundation of America (AAFA). Allergens and Allergic Asthma. Available at: https://www.aafa.org/allergic-asthma

20. Wark P.A.B., Johnston S.L., Bucchieri F. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J. Exp. Med. 2005; 201 (6): 937–947. DOI: 10.1084/jem.20041901.

21. Jacobsen E.A., Helmers R.A., Lee J.J., Lee N.A. The expanding role(s) of eosinophils in health and disease. Blood. 2012; 120 (19): 3882–3890. DOI: 10.1182/blood-2012-06-330845.

22. Min A., Lee Y.A., Kim K.A. et al. NOX2‐derived ROS‐mediated surface translocation of BLT1 is essential for exocytosis in human eosinophils induced by LTB4. Int. Arch. Allergy Immunol. 2014; 165 (1): 40–51. DOI: 10.1159/000366277.

23. Jaquet V., Bedard K. Editorial: Genetic mapping – the path of discovery for novel functions of the NOX NADPH oxidases. J. Leukoс. Biol. 2009; 86 (3): 461–463. DOI: 10.1189/jlb.0409243.

24. Nakagome K., Nagata M. Involvement and possible role of eosinophils in asthma exacerbation. Front. Immunol. 2018; 9: 2220. DOI: 10.3389/fimmu.2018.02220.

25. Liu F., Xu A., Zhang Y. et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int. J. Infect. Dis. 2020; 95: 183–191. DOI: 10.1016/j.ijid.2020.03.013.

26. Radzikowska U., Ding M., Tan G. et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020; 75 (11): 2829–2845. DOI: 10.1111/all.14429.

27. Brake S.J., Barnsley K., Lu W. et al. Smoking upregulates angiotensin- converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). J. Clin. Med. 2020; 9 (3): 841. DOI: 10.3390/jcm9030841.

28. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239–1242. DOI: 10.1001/jama.2020.2648.

29. Bhatraju P.K., Ghassemieh B.J., Nichols M. et al. Covid-19 in critically ill patients in the seattle region – case series. N. Engl. J. Med. 2020; 382 (21): 2012–2022. DOI: 10.1056/NEJMoa2004500.

30. Yang J., Koh H., Moon S. et al. Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J. Allergy Clin. Immunol. 2020; 146 (4): 790–798. DOI: 10.1016/j.jaci.2020.08.008.

31. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5.

32. Kimura H., Francisco D., Conway M. et al. Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J. Allergy Clin. Immunol. 2020; 146 (1): 80–88.e8. DOI: 10.1016/j.jaci.2020.05.004.

33. Dong X., Cao Y.Y., Lu X.X. et al. Eleven faces of coronavirus disease 2019. Allergy. 2020; 75 (7): 1699–1709. DOI: 10.1111/all.14289.

34. Zhu Z., Hasegawa K., Ma B. et al. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J. Allergy Clin. Immunol. 2020; 146 (2): 327–329.e4. DOI: 10.1016/j.jaci.2020.06.001.

35. Skevaki C., Karsonova A., Karaulov A. et al. Asthma-associated risk for COVID-19 development. J. Allergy Clin. Immunol. 2020; 146 (6): 1295–1301. DOI: 10.1016/j.jaci.2020.09.017.

36. Del Rio C., Malani O.N. COVID-19 – new insights on a rapidly changing epidemic. JAMA. 2020; 323 (14): 1339–1340. DOI: 10.1001/jama.2020.3072.

37. Bloom C.I., Drake T.M., Docherty A.B. et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir. Med. 2021; 9 (7): 699–711. DOI: 10.1016/S2213-2600(21)00013-8.

38. Morais-Almeida М., Aguiar R., Martin B. et al. COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organ. J. 2020; 13 (5): 100126. DOI: 10.1016/j.waojou.2020.100126.

39. Abrams E., Jong G., Yang C. Paediatric asthma and COVID-19. Ottawa: Canadian Paediatric Society; 2020. Available at: https://www.cps.ca/en/documents/position/paediatric-asthma-and-covid-19

40. Liu S., Zhi Y., Ying S. COVID-19 and asthma: reflection during the pandemic. Clin. Rev. Allergy Immunol. 2020; 59 (1): 78–88. DOI: 10.1007/s12016-020-08797-3.

41. Klimek L., Jutel M., Akdis C. et al. Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement. Allergy. 2020; 75 (7): 1546–1554. DOI: 10.1111/all.14336.

42. Pfaar O., Klimek L., Jutel M. et al. COVID-19 pandemic: practical considerations on the organization of an allergy clinic an EAACI/ ARIA position paper. Allergy. 2021; 76 (3): 648–676. DOI: 10.1111/all.14453.

43. Klimek L., Pfaar O., Worm M. et al. Allergen immunotherapy in the current COVID-19 pandemic: a position paper of AeDA, ARIA, EAACI, DGAKI and GPA. Allergol. Select. 2020; 4 (1): 44–52. DOI: 10.5414/ALX02147E.